Replies to post #120888 on Anavex Life Sciences Corp (AVXL)

[nidan7500]

It was discussed at length back in late July after the Company skipped the AAIC without explanation.

Additionally, it is now becoming clear that any discussion during AAIC on future plans/trials would have been at least risky but certainly a waste of everyone's time considering the now understood changes in trials protocol. Recent speeches/news from FDA director level makes it clear that BP will be in line w/the little people trying to devise trials that really prove something . (so we got that going for us)

Looks like major league financial/technical/political scrum is underway on how trials (read approvals and big $$$) will be done. Finally, the rules that have produced almost nothing of CNS treatment consequence in past 30 years are being scrutinized /evaluated ...and guess what...THEY SUCK. It is time now for people with guts and brains to get a system that is effective in place while they simultaneously disassemble the hopeless mess we have in place today. It's gonna be a while. Too bad we cannot get information on how that is going. Instead we await our RETT trials protocol that is somewhere in the blender.

[sokol]

I, too, am not a securities lawyer. However, my lay understanding is that this company, as any company, must disclose a material fact. If Anavex knows the Alzheimer's clinical trial results are negative, that's a material fact, and there is a duty to disclose that. However, if there is ambiguous information about the trial, which the company is still studying, I do not believe that has to be disclosed. Lastly, I believe though that it would be a mistake for the CEO to continue to purchase shares, even in small in amounts, if the CEO knows there may be negative information about the clinical trial because that may be alleged to be misleading -- leading investors to think that all is well when all is not well if the trial may be doubtful about whether the drug works.